Richard Grove

1.2k total citations
21 papers, 747 citations indexed

About

Richard Grove is a scholar working on Infectious Diseases, Virology and Pathology and Forensic Medicine. According to data from OpenAlex, Richard Grove has authored 21 papers receiving a total of 747 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Infectious Diseases, 9 papers in Virology and 8 papers in Pathology and Forensic Medicine. Recurrent topics in Richard Grove's work include HIV/AIDS drug development and treatment (11 papers), HIV Research and Treatment (9 papers) and Multiple Sclerosis Research Studies (8 papers). Richard Grove is often cited by papers focused on HIV/AIDS drug development and treatment (11 papers), HIV Research and Treatment (9 papers) and Multiple Sclerosis Research Studies (8 papers). Richard Grove collaborates with scholars based in United Kingdom, United States and Canada. Richard Grove's co-authors include Per Soelberg Sørensen, Frederick J. Derosier, Eva Havrdová, Steen Lisby, Massimo Filippi, Jelena Drulović, Susan VanMeter, Jerry M. Tolson, Amit Bar‐Or and Daren Austin and has published in prestigious journals such as SHILAP Revista de lepidopterología, Neurology and The Lancet Neurology.

In The Last Decade

Richard Grove

19 papers receiving 733 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Richard Grove United Kingdom	10	410	312	155	125	120	21	747
Judith Fraussen Belgium	17	355 0.9×	554 1.8×	186 1.2×	204 1.6×	80 0.7×	28	1.1k
Kathrine E. Attfield United Kingdom	13	271 0.7×	469 1.5×	74 0.5×	317 2.5×	114 0.9×	16	979
Alyssa Nylander United States	6	380 0.9×	438 1.4×	95 0.6×	173 1.4×	86 0.7×	12	866
Yusei Miyazaki Japan	18	857 2.1×	840 2.7×	414 2.7×	232 1.9×	70 0.6×	65	1.6k
А. Н. Бойко Russia	12	707 1.7×	247 0.8×	248 1.6×	143 1.1×	46 0.4×	75	995
Mirjam Korporal Germany	12	374 0.9×	791 2.5×	89 0.6×	117 0.9×	27 0.2×	12	1.1k
Anna R. Tröscher Austria	10	232 0.6×	221 0.7×	148 1.0×	160 1.3×	22 0.2×	14	667
Mark Marriott Australia	13	296 0.7×	207 0.7×	133 0.9×	130 1.0×	97 0.8×	28	758
Jonathan O. Harris United States	6	454 1.1×	61 0.2×	247 1.6×	481 3.8×	87 0.7×	6	1.1k
Robert B. Ratts United States	12	287 0.7×	590 1.9×	63 0.4×	97 0.8×	25 0.2×	15	807

Countries citing papers authored by Richard Grove

Since Specialization

Citations

This map shows the geographic impact of Richard Grove's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Grove with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Grove more than expected).

Fields of papers citing papers by Richard Grove

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Grove. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Grove. The network helps show where Richard Grove may publish in the future.

Co-authorship network of co-authors of Richard Grove

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Grove. A scholar is included among the top collaborators of Richard Grove based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Grove. Richard Grove is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rolle, Charlotte-Paige, José Ramón Arribas, Roberto Ortiz, et al.. (2025). Efficacy and Safety Outcomes in Adults Initiating Dolutegravir/Lamivudine With High Viral Load in the GEMINI-1/-2 and STAT Trials. Open Forum Infectious Diseases. 12(3). ofaf135–ofaf135.

Patel, Parul, Ana Milinkovic, Richard Grove, et al.. (2025). Hypertension and blood pressure changes with dolutegravir or comparator antiretroviral therapy in randomized trials through 96 weeks. Journal of Antimicrobial Chemotherapy. 80(9). 2375–2383.

Walmsley, Sharon, Don Smith, Miguel Górgolas, et al.. (2024). Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies. AIDS Research and Therapy. 21(1). 17–17. 1 indexed citations

Polli, Joseph W., Parul Patel, Richard Grove, et al.. (2023). Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials. The Journal of Infectious Diseases. 230(1). e34–e42. 10 indexed citations

Grove, Richard, et al.. (2023). An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor–based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1. AIDS Research and Therapy. 20(1). 17–17. 3 indexed citations

Madero, Juan Sierra, Núria Espinosa, Roberto Gulminetti, et al.. (2023). Impact of Treatment Adherence on Efficacy of Dolutegravir + Lamivudine and Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Week 144 Analysis of the GEMINI-1 and GEMINI-2 Clinical Studies. JAIDS Journal of Acquired Immune Deficiency Syndromes. 94(3). e9–e12. 3 indexed citations

Rawlings, M. Keith, Romina Quercia, Richard Grove, et al.. (2022). Evaluating Diversity in Randomized Clinical Trials of Dolutegravir-Based Antiretroviral Therapy Regimens: Pooled 48-Week Analyses by Race, Sex, and Regional Subgroups. Open Forum Infectious Diseases. 9(8). ofac304–ofac304. 3 indexed citations

Ait‐Khaled, Mounir, Juan Sierra Madero, Vicente Estrada, et al.. (2021). Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studies. SHILAP Revista de lepidopterología. 23(1). 9–14. 6 indexed citations

Kolk, M. van der, et al.. (2021). Dolutegravir-based regimens in treatment-naive and treatment-experienced aging populations: analyses of 6 phase III clinical trials. SHILAP Revista de lepidopterología. 22(2). 46–54. 7 indexed citations

10.

Ait‐Khaled, Mounir, Choy Man, Jörg Sievers, et al.. (2020). 1024. Impact of Treatment Adherence on Efficacy of DTG/3TC and DTG + TDF/FTC: Pooled Analysis of the GEMINI 1 and 2 Clinical Trials. Open Forum Infectious Diseases. 7(Supplement_1). S541–S542. 1 indexed citations

11.

Snedecor, Sonya J., et al.. (2019). Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis. BMC Infectious Diseases. 19(1). 484–484. 34 indexed citations

12.

Bar‐Or, Amit, Richard Grove, Daren Austin, et al.. (2018). Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis. Neurology. 90(20). e1805–e1814. 154 indexed citations

13.

Schwartzbach, Caryl, Richard Grove, Robert A. Brown, et al.. (2016). Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study. Journal of Neurology. 264(2). 304–315. 86 indexed citations

14.

Grove, Richard, Conn Harrington, I.J.M. Beresford, et al.. (2014). A Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of the H<sub>3</sub> Receptor Antagonist, GSK239512 as a Monotherapy in Subjects with Mild-to-Moderate Alzheimer’s Disease. Current Alzheimer Research. 11(1). 47–58. 87 indexed citations

15.

Bar‐Or, Amit, et al.. (2014). The MIRROR Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Investigate the Safety and MRI Efficacy of Subcutaneous Ofatumumab in Subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) (S23.006). Neurology. 82(10_supplement). 22 indexed citations

16.

Sørensen, Per Soelberg, Steen Lisby, Richard Grove, et al.. (2014). Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis. Neurology. 82(7). 573–581. 218 indexed citations

17.

Bar‐Or, Amit, et al.. (2014). The MIRROR Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Investigate the Safety and MRI Efficacy of Subcutaneous Ofatumumab in Subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) (I7-1.007). Neurology. 82(10_supplement). 3 indexed citations

18.

Grove, Richard, S. D. Shackelford, Sieghart Sopper, et al.. (2013). Leukocyte counts in cerebrospinal fluid and blood following firategrast treatment in subjects with relapsing forms of multiple sclerosis. European Journal of Neurology. 20(7). 1032–1042. 8 indexed citations

19.

Battaglini, Marco, Francesca Rossi, Richard Grove, et al.. (2013). Automated identification of brain new lesions in multiple sclerosis using subtraction images. Journal of Magnetic Resonance Imaging. 39(6). 1543–1549. 40 indexed citations

20.

Miller, David H., Thomas Weber, Richard Grove, et al.. (2012). Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial. The Lancet Neurology. 11(2). 131–139. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact